Therapeutic drug monitoring in kidney and liver transplantation: current advances and future directions

References

• Koch-Weser J. Serum drug concentrations as therapeutic guides. N Engl J Med. 1972;287(5):227–231. doi: 10.1056/NEJM197208032870505
   PubMed Web of Science ®Google Scholar
• Oellerich M, Kanzow P, Walson PD. Therapeutic drug monitoring – key to personalized pharmacotherapy. Clin Biochem. 2017;50(7–8):375–379. doi: 10.1016/j.clinbiochem.2017.01.007
   PubMed Web of Science ®Google Scholar
• Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dialysis Transplantation. 2001;16(9):1905–1909. doi: 10.1093/ndt/16.9.1905
   PubMed Web of Science ®Google Scholar
• Pascual J, Berger SP, Witzke O, et al. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. JASN. 2018;29(7):1979–1991. doi: 10.1681/ASN.2018010009
   Web of Science ®Google Scholar
• Marcén R, Fernández-Rodriguez A, Rodríguez-Mendiola N, et al. Evolution of rejection rates and kidney graft survival: a historical analysis. In: Transplantation Proceedings; February 22-25, 2009; Barcelona. 2009. p. 2357–2359.
   Google Scholar
• Kuypers DRJ, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred De novo renal transplant recipients. Clin Pharmacokinet. 2004;43(11):741–762. doi: 10.2165/00003088-200443110-00005
   PubMed Web of Science ®Google Scholar
• Vanhove T, Annaert P, Kuypers DRJ. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev. 2016;48(1):88–112. doi: 10.3109/03602532.2016.1151037
   PubMed Web of Science ®Google Scholar
• Sallustio BC, Noll BD, Hu R, et al. Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. Brit J Clinical Pharma. 2021;87(10):3901–3909. doi: 10.1111/bcp.14806
   PubMed Web of Science ®Google Scholar
• Bentata Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artif Organs. 2020;44:140–152. doi: 10.1111/aor.13551
   PubMed Web of Science ®Google Scholar
• Laskow DA, Vincenti F, Neylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States multicenter FK506 kidney transplant Group1. Transplantation. 1996;62:900–905. doi: 10.1097/00007890-199610150-00005
   PubMed Web of Science ®Google Scholar
• Brunet M, van Gelder T, Åsberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261–307. doi: 10.1097/FTD.0000000000000640
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562–2575. doi: 10.1056/NEJMoa067411
   PubMed Web of Science ®Google Scholar
• Kuypers D. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther. 2004;75(5):434–447. doi: 10.1016/j.clpt.2003.12.009
   PubMed Web of Science ®Google Scholar
• Kershner RP, Fitzsimmons WE. relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996;62:920–926. doi: 10.1097/00007890-199610150-00009
   PubMed Web of Science ®Google Scholar
• Nguyen TVA, Nguyen HD, Nguyen TLH, et al. Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation. BMC Nephrol. 2023;24(1):131. doi: 10.1186/s12882-023-03188-0
   PubMed Web of Science ®Google Scholar
• Davis S, Gralla J, Klem P, et al. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant. 2018;18(4):907–915. doi: 10.1111/ajt.14504
   PubMed Web of Science ®Google Scholar
• Gatault P, Kamar N, Büchler M, et al. Reduction of extended-release tacrolimus dose in Low-Immunological-Risk kidney transplant recipients increases Risk of rejection and appearance of donor-specific antibodies: a randomized study. Am J Transplant. 2017;17(5):1370–1379. doi: 10.1111/ajt.14109
   PubMed Web of Science ®Google Scholar
• Meziyerh S, van Gelder T, Kers J, et al. Tacrolimus and mycophenolic acid exposure are associated with Biopsy‐Proven acute rejection: a study to provide evidence for Longer‐Term target ranges. Clin Pharm Ther. 2023;114(1):192–200. doi: 10.1002/cpt.2915
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Shaw LM, Sarkozi L, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001;41(5):542–551. doi: 10.1177/00912700122010429
   PubMed Web of Science ®Google Scholar
• Rodríguez-Perálvarez M, Germani G, Darius T, et al. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant. 2012;12(10):2797–2814. doi: 10.1111/j.1600-6143.2012.04140.x
   PubMedGoogle Scholar
• Lemaitre F, Monchaud C, Woillard J-B, et al. Synthèse des recommandations de l’International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) sur le suivi thérapeutique pharmacologique du tacrolimus. Therapies. 2020;75(6):681–685. doi: 10.1016/j.therap.2020.06.004
   PubMedGoogle Scholar
• Lemaitre F, Tron C, Renard T, et al. Redefining therapeutic drug monitoring of tacrolimus in patients undergoing liver transplantation: a target trough concentration of 4–7 ng/mL during the first month after liver transplantation is safe and improves graft and renal function. Ther Drug Monit. 2020;42(5):671–678. doi: 10.1097/FTD.0000000000000779
   PubMed Web of Science ®Google Scholar
• Rodríguez-Perálvarez M, Germani G, Papastergiou V, et al. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J hepatol. 2013;58(2):262–270. doi: 10.1016/j.jhep.2012.09.019
   PubMed Web of Science ®Google Scholar
• Rodríguez-Perálvarez M, Colmenero J, González A, et al. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation. Am J Transplant. 2022;22(6):1671–1682. doi: 10.1111/ajt.17021
   PubMed Web of Science ®Google Scholar
• Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet. 1999;353(9158):1083–1091. doi: 10.1016/S0140-6736(98)07493-5
   PubMed Web of Science ®Google Scholar
• Hardinger KL, Bohl DL, Schnitzler MA, et al. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. Transplantation. 2005;80(1):41–46. doi: 10.1097/01.TP.0000162980.68628.5A
   PubMed Web of Science ®Google Scholar
• Keown P, Niese D, behalf of the Internatial Sandimmun Neoral Study Group, o.n, on behalf of the International Sandimmun Neoral Study Group. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. Kidney Int. 1998;54(3):938–944. doi: 10.1046/j.1523-1755.1998.00042.x
   PubMed Web of Science ®Google Scholar
• Barone G, Chang CT, Choc MG, et al. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients: transplantation. Transplantation. 1996;61(6):875–880. doi: 10.1097/00007890-199603270-00005
   PubMed Web of Science ®Google Scholar
• Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2(2):374–384. doi: 10.2215/CJN.03791106
   PubMed Web of Science ®Google Scholar
• Vavic N, Ignjatovic L, Draskovic B, et al. Efikasnost terapijskog monitoringa ciklosporina odredjivanjem C2 i PIK0−4 tokom prva 24 meseca posle transplantacije bubrega. VSP. 2008;65(2):119–127. doi: 10.2298/VSP0802119V
   Google Scholar
• Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation. 1999;68(1):55–62. doi: 10.1097/00007890-199907150-00011
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Barbeito R, for the Simulect US01 Study Group. Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts: cyclosporine C2 in kidney transplantation. Clin Transplant. 2002;16(5):378–382. doi: 10.1034/j.1399-0012.2002.02036.x
   PubMed Web of Science ®Google Scholar
• Hardinger KL, Schnitzler MA, Koch MJ, et al. Cyclosporine minimization and cost reduction in renal transplant recipients receiving a C2-monitored, cyclosporine-based quadruple immunosuppressive regimen. Transplantation. 2004;78(8):1198–1203. doi: 10.1097/01.TP.0000137423.01887.7D
   PubMed Web of Science ®Google Scholar
• Stefoni S, Midtved K, Cole E, et al. Efficacy and safety outcomes among De novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter study. Transplantation. 2005;79(5):577–583. doi: 10.1097/01.TP.0000153158.91683.34
   PubMed Web of Science ®Google Scholar
• Le Meur Y, Büchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7(11):2496–2503. doi: 10.1111/j.1600-6143.2007.01983.x
   PubMed Web of Science ®Google Scholar
• Starzl TE, Iwatsuki S, Shaw BW Jr., et al. Liver transplantation in the Ciclosporin Era. In: Borel J, editor. Chemical immunology and allergy [internet]. Basel: KARGER; 1986 [cited 2023 Aug 8]. p. 366–394. Available from: https://www.karger.com/Article/FullText/318481
   Google Scholar
• Schrem H, Lück R, Becker T, et al. Update on liver transplantation using cyclosporine. In: Transplantation Proceedings. 2004. Vol. 36. p. 2525–2531.
   Google Scholar
• Halloran PF, Helms LMH, Kung L, et al. The temporal profile of calcineurin inhibitor by cyclosporine in vivo1. Transplantation. 1999;68(9):1356–1361. doi: 10.1097/00007890-199911150-00023
   PubMed Web of Science ®Google Scholar
• Grant D, Kneteman N, Tchervenkov J, et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8)1,2. Transplantation. 1999;67(8):1133–1137. doi: 10.1097/00007890-199904270-00008
   PubMed Web of Science ®Google Scholar
• Levy G, Thervet E, Lake J, et al. Patient management by Neoral C2 monitoring: an international consensus statement1. Transplantation. 2002;73(Supplement):S12–S18. doi: 10.1097/00007890-200205151-00003
   PubMedGoogle Scholar
• Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral?* formulation. BioDrugs. 2001;15(5):279–290. doi: 10.2165/00063030-200115050-00001
   PubMed Web of Science ®Google Scholar
• Tett SE, Saint-Marcoux F, Staatz CE, et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplantation Rev. 2011;25(2):47–57. doi: 10.1016/j.trre.2010.06.001
   Web of Science ®Google Scholar
• Boudjema K, Camus C, Saliba F, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant. 2011;11(5):965–976. doi: 10.1111/j.1600-6143.2011.03486.x
   PubMed Web of Science ®Google Scholar
• van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86(8):1043–1051. doi: 10.1097/TP.0b013e318186f98a.
   PubMed Web of Science ®Google Scholar
• Gaston RS, Kaplan B, Shah T, et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the opticept trial. Am J Transplant. 2009;9(7):1607–1619. doi: 10.1111/j.1600-6143.2009.02668.x
   PubMed Web of Science ®Google Scholar
• Tredger JM, Brown NW, Adams J, et al. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl. 2004;10(4):492–502. doi: 10.1002/lt.20124
   PubMed Web of Science ®Google Scholar
• Sarvary E, Nemes B, Varga M, et al. Significance of mycophenolate monitoring in liver transplant recipients: toward the cut-off level. In: Transplantation Proceedings; Budapest, Hungary. 2012p. 2157–2161;44.
   Google Scholar
• Saliba F, Rostaing L, Gugenheim J, et al. Corticosteroid-sparing and optimization of mycophenolic acid exposure in liver transplant recipients receiving mycophenolate mofetil and tacrolimus: a randomized, multicenter study. Transplantation. 2016;100(8):1705–1713. doi: 10.1097/TP.0000000000001228
   PubMed Web of Science ®Google Scholar
• Mao B, Zhang Q, Ma L, et al. Overview of research into mTOR inhibitors. Molecules. 2022;27(16):5295. doi: 10.3390/molecules27165295
   PubMed Web of Science ®Google Scholar
• Kahan B, Napoli K, Kelly P, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity: sirolimus concentration monitoring. Clin Transplan. 2000;14(2):97–109. doi: 10.1034/j.1399-0012.2000.140201.x
   PubMed Web of Science ®Google Scholar
• Gonwa T, Mendez R, Yang HC, et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months1. Transplantation. 2003;75(8):1213–1220. doi: 10.1097/01.TP.0000062837.99400.60
   PubMed Web of Science ®Google Scholar
• Vitko S, Wlodarczyk Z, Kyllönen L, et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. Am J Transplant. 2006;6(3):531–538. doi: 10.1111/j.1600-6143.2005.01193.x
   PubMed Web of Science ®Google Scholar
• Stegall MD, Larson TS, Prieto M, et al. Kidney transplantation without calcineurin inhibitors using sirolimus. In: Transplantation Proceedings. 2003. p. S125–S127.
   Google Scholar
• Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine1. Transplantation. 2002;74(8):1070–1076. doi: 10.1097/00007890-200210270-00002
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation. 2002;73(6):920–925. doi: 10.1097/00007890-200203270-00016
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in De novo kidney transplantation. Ther Drug Monit. 2004;26(5):499–505. doi: 10.1097/00007691-200410000-00007
   PubMed Web of Science ®Google Scholar
• Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl. 2006;12(11):1640–1648. doi: 10.1002/lt.20707
   PubMed Web of Science ®Google Scholar
• Guo Y, Wang J, Wu W, et al. Incidence of ischemia reperfusion injury related biliary complications in liver transplantation: effect of different types of donors. In: Transplantation Proceedings. 2022. Vol. 54. p. 1865–1873.
   Google Scholar
• Saliba F, Fischer L, de Simone P, et al. Association between renal dysfunction and major adverse cardiac events after liver transplantation: evidence from an international randomized trial of everolimus-based immunosuppression. Ann Transplant. 2018;23:751–757. doi: 10.12659/AOT.911030
   PubMed Web of Science ®Google Scholar
• Sterneck M, Kaiser GM, Heyne N, et al. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study. Clin Transplant. 2016;30(6):741–748. doi: 10.1111/ctr.12744
   PubMed Web of Science ®Google Scholar
• De Simone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial: everolimus with CNI discontinuation. Liver Transpl. 2009;15(10):1262–1269. doi: 10.1002/lt.21827
   PubMed Web of Science ®Google Scholar
• Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation—PROTECT. Am J Transplant. 2012;12(7):1855–1865. doi: 10.1111/j.1600-6143.2012.04049.x
   PubMed Web of Science ®Google Scholar
• Saliba F, Dharancy S, Lorho R, et al. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis: everolimus in maintenance liver transplant patients. Liver Transpl. 2011;17(8):905–913. doi: 10.1002/lt.22292
   PubMed Web of Science ®Google Scholar
• Capron A, Haufroid V, Wallemacq P. Intra-cellular immunosuppressive drugs monitoring: a step forward towards better therapeutic efficacy after organ transplantation? Pharmacol Res. 2016;111:610–618. doi: 10.1016/j.phrs.2016.07.027
   PubMed Web of Science ®Google Scholar
• Lemaitre F, Antignac M, Verdier M-C, et al. Opportunity to monitor immunosuppressive drugs in peripheral blood mononuclear cells: where are we and where are we going? Pharmacol Res. 2013;74:109–112. doi: 10.1016/j.phrs.2013.06.003
   PubMed Web of Science ®Google Scholar
• Tron C, Ferrand-Sorre M-J, Querzerho-Raguideau J, et al. Volumetric absorptive microsampling for the quantification of tacrolimus in capillary blood by high performance liquid chromatography-tandem mass spectrometry. Journal Of Chromatography B. 2021;1165:122521. doi: 10.1016/j.jchromb.2020.122521
   PubMed Web of Science ®Google Scholar
• Koster RA, Alffenaar J-W, Botma R, et al. The relation of the number of hydrogen-bond acceptors with recoveries of immunosuppressants in DBS analysis. Bioanalysis. 2015;7(14):1717–1722. doi: 10.4155/bio.15.94
   PubMed Web of Science ®Google Scholar
• Zwart TC, Gokoel SRM, van der Boog PJM, et al. Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device: immunosuppressant TDM using dried blood spots. Br J Clin Pharmacol. 2018;84(12):2889–2902. doi: 10.1111/bcp.13755
   PubMed Web of Science ®Google Scholar
• Haverals L, Roosens L, Wouters K, et al. Does the tacrolimus trough level adequately predict drug exposure in patients requiring a High tacrolimus dose? Transplant Direct. 2023;9(4):e1439. doi: 10.1097/TXD.0000000000001439
   PubMed Web of Science ®Google Scholar
• Couette A, Tron C, Golbin L, et al. Area under the curve of tacrolimus using microsampling devices: towards precision medicine in solid organ transplantation? Eur J Clin Pharmacol. 2023;79(11):1549–1556. doi: 10.1007/s00228-023-03566-5
   PubMed Web of Science ®Google Scholar
• Tron C, Lemaitre F. Perspective on the use of limited sampling strategies to assess drug exposure in the era of microsampling. Ther Drug Monit. 2021;43(6):812–813. doi: 10.1097/FTD.0000000000000923
   PubMed Web of Science ®Google Scholar
• Golbin L, Tron C, Franck B, et al. First experience of optimization of tacrolimus therapeutic drug monitoring in a patient cotreated with nirmatrelvir/ritonavir: how microsampling approach changes everything. Transplantation. 2023;107(2):e68–e69. doi: 10.1097/TP.0000000000004430
   PubMed Web of Science ®Google Scholar
• Lemaitre F, Hesselink DA. TDM is alive and kicking! Ther Drug Monit. 2023;45(1):3–5. doi: 10.1097/FTD.0000000000001034
   PubMed Web of Science ®Google Scholar
• Knight SR, Thorne A, Lo Faro ML. Donor-specific Cell-free DNA as a biomarker in solid organ transplantation: a systematic review. Transplantation. 2019;103(2):273–283. doi: 10.1097/TP.0000000000002482
   PubMed Web of Science ®Google Scholar
• van Rijn A, Roos R, Dekker F, et al. Torque teno virus load as marker of rejection and infection in solid organ transplantation – a systematic review and meta‐analysis. Rev Med Virol. 2023 [cited 2023 Aug 8];33(1). doi: 10.1002/rmv.2393
   PubMed Web of Science ®Google Scholar